Coculture of cancer cells with platelets increases their survival and metastasis by activating the TGFβ/Smad/PAI-1 and PI3K/AKT pathways

When cancer cells enter the bloodstream, they can interact with platelets to acquire stronger survival and metastatic abilities. To elucidate the underlying mechanisms, we cocultured metastatic melanoma and triple-negative breast cancer cells with species-homologous platelets. We found that cocultured cancer cells displayed higher viabilities in circulation, stronger capacities for cell migration, invasion, and colony formation in vitro, and more tumorigenesis and metastasis in mice. RNA sequencing analysis revealed that the level of serpin family E member 1 (SERPINE1) was significantly upregulated in cocultured cancer cells. Knockdown of SERPINE1 reversed the coculture-elevated survival and metastatic phenotypes of cancer cells. Mechanistic studies indicated that coculture with platelets activated the TGFβ/Smad pathway to induce SERPINE1 expression in cancer cells, which encodes plasminogen activator inhibitor 1 (PAI-1). PAI-1 then activated PI3K to increase the phosphorylation of AKTThr308 and Bad to elevate Bcl-2, which enhanced cell survival in circulation. Moreover, higher levels of PAI-1 were detected in metastatic tumors from melanoma and triple-negative breast cancer patients than in normal tissues, and high levels of PAI-1 were associated with a shorter overall survival time and worse disease progression in breast cancer. PAI-1 may act as a potential biomarker for detecting and treating metastatic tumor cells.

[1]  K. Pantel,et al.  Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance. , 2022, Cell reports.

[2]  Sanggu Kim,et al.  An Insight into Recent Advances on Platelet Function in Health and Disease , 2022, International journal of molecular sciences.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  S. Singh,et al.  p32 promotes melanoma progression and metastasis by targeting EMT markers, Akt/PKB pathway, and tumor microenvironment , 2021, Cell Death & Disease.

[5]  K. Luo,et al.  Desmosomal proteins of DSC2 and PKP1 promote cancer cells survival and metastasis by increasing cluster formation in circulatory system , 2021, Science advances.

[6]  J. L. Corrons,et al.  Concise review: how do red blood cells born, live, and die? , 2021, Annals of Hematology.

[7]  N. Maftoon,et al.  Interactions of platelets with circulating tumor cells contribute to cancer metastasis , 2021, Scientific Reports.

[8]  K. Luo,et al.  Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells , 2021, Oncogene.

[9]  Y. Kakeji,et al.  PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages , 2020, Laboratory Investigation.

[10]  E. Nice,et al.  Emerging role of tumor cell plasticity in modifying therapeutic response , 2020, Signal Transduction and Targeted Therapy.

[11]  Y. DeClerck,et al.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding , 2019, Cancer and Metastasis Reviews.

[12]  M. R. Ruocco,et al.  Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity , 2019, Cells.

[13]  Le-hua Shi,et al.  Survival Mechanisms and Influence Factors of Circulating Tumor Cells , 2018, BioMed research international.

[14]  S. Yuan,et al.  Plasminogen activator inhibitor-1 in cancer research. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  N. Sun,et al.  Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance , 2018, Cell Death & Disease.

[16]  A. Sood,et al.  The Platelet Lifeline to Cancer: Challenges and Opportunities. , 2018, Cancer cell.

[17]  Shaowei Li,et al.  Fluid shear stress and tumor metastasis. , 2018, American journal of cancer research.

[18]  K. Hunter,et al.  Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration. , 2018, Cell reports.

[19]  R. Flaumenhaft,et al.  The life cycle of platelet granules , 2018, F1000Research.

[20]  Stephen T. C. Wong,et al.  Platelets reduce anoikis and promote metastasis by activating YAP1 signaling , 2017, Nature Communications.

[21]  R. Muschel,et al.  Protocol for Murine/Mouse Platelets Isolation and Their Reintroduction in vivo. , 2017, Bio-protocol.

[22]  Kathy Qian Luo,et al.  High Shear Stresses under Exercise Condition Destroy Circulating Tumor Cells in a Microfluidic System , 2017, Scientific Reports.

[23]  O. Peyruchaud,et al.  Metastasis: new functional implications of platelets and megakaryocytes. , 2016, Blood.

[24]  A. Noël,et al.  Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells. , 2016, Cancer research.

[25]  E. Tan,et al.  High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin , 2016, Oncotarget.

[26]  D. Whiteman,et al.  The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. , 2016, The Journal of investigative dermatology.

[27]  G. FitzGerald,et al.  Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells , 2016, Oncotarget.

[28]  Jialan Shi,et al.  Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients , 2016, Journal of Experimental & Clinical Cancer Research.

[29]  R. Mangues,et al.  Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients , 2015, Oncotarget.

[30]  Y. DeClerck,et al.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. , 2015, Cancer research.

[31]  A. Franco,et al.  Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.

[32]  P. Brown,et al.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. , 2014, The Lancet. Oncology.

[33]  R. Hynes,et al.  Platelets guide the formation of early metastatic niches , 2014, Proceedings of the National Academy of Sciences.

[34]  Li-jing Wang,et al.  P-Selectin-Mediated Platelet Adhesion Promotes the Metastasis of Murine Melanoma Cells , 2014, PloS one.

[35]  Richard O Hynes,et al.  The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. , 2012, Cancer discovery.

[36]  B. Chong,et al.  Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. , 2012, Cancer research.

[37]  W. Chiu,et al.  Paraneoplastic thrombocytosis in ovarian cancer. , 2012, The New England journal of medicine.

[38]  H. Rammensee,et al.  Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. , 2012, Cancer research.

[39]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[40]  E. E. Vincent,et al.  Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer , 2011, British Journal of Cancer.

[41]  Mehmet Toner,et al.  Circulating tumor cells: approaches to isolation and characterization , 2011, The Journal of cell biology.

[42]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[43]  S. Russell,et al.  Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models , 2009, Journal of thrombosis and haemostasis : JTH.

[44]  H. Salih,et al.  Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. , 2009, Cancer research.

[45]  N. Brünner,et al.  Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. , 2008, Neoplasia.

[46]  J. Gilabert-Estellés,et al.  Fibrinolysis: the key to new pathogenetic mechanisms. , 2008, Current medicinal chemistry.

[47]  J. Whisstock,et al.  An overview of the serpin superfamily , 2006, Genome Biology.

[48]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[49]  Michael Gnant,et al.  Impact of pretreatment thrombocytosis on survival in primary breast cancer , 2003, Thrombosis and Haemostasis.

[50]  R. Czekay,et al.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins , 2003, The Journal of cell biology.

[51]  H. Imamura,et al.  Poor prognosis associated with thrombocytosis in patients with gastric cancer , 2002, Annals of Surgical Oncology.

[52]  D. Webb,et al.  Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes Mcf-7 Cell Growth , 2001, The Journal of cell biology.

[53]  Nils Brünner,et al.  The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin , 2001, The Journal of cell biology.

[54]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[55]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[56]  B. Echtenacher,et al.  Lysis of tumor cells by natural killer cells in mice is impeded by platelets. , 1999, Cancer research.

[57]  H. Nielsen,et al.  Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer , 1998, BMJ.

[58]  N. Milman,et al.  Prognostic significance of thrombocytosis in patients with primary lung cancer. , 1996, The European respiratory journal.

[59]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[60]  K. Becker,et al.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. , 1994, Cancer research.

[61]  L. Baud,et al.  Protection from tumor necrosis factor-mediated cytolysis by platelets. , 1993, The American journal of pathology.

[62]  J. Mimuro.  [Type 1 plasminogen activator inhibitor: its role in biological reactions]. , 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[63]  D. Lawrence,et al.  Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[64]  I. Fidler.  The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. , 1973, European journal of cancer.

[65]  E. Gulbins,et al.  Melanoma cell metastasis via P-selectin-mediated activation of acid sphingomyelinase in platelets , 2016, Clinical & Experimental Metastasis.

[66]  J. Harmon,et al.  Metastasis-promoting role of extravasated platelet activation in tumor. , 2015, The Journal of surgical research.

[67]  E. Sunami,et al.  Impact of Preoperative Thrombocytosis on the Survival of Patients with Primary Colorectal Cancer , 2011, World Journal of Surgery.

[68]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[69]  Massimo Libra,et al.  Akt as a therapeutic target in cancer. , 2008, Expert opinion on therapeutic targets.

[70]  Masahiko Zuka,et al.  Platelet glycoprotein Ib alpha supports experimental lung metastasis. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[71]  V. Turitto.  Blood viscosity, mass transport, and thrombogenesis. , 1982, Progress in hemostasis and thrombosis.